| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PAP |
| Uniprot No | P15309 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 33-386aa |
| 氨基酸序列 | KELKFVTLVF RHGDRSPIDT FPTDPIKESS WPQGFGQLTQ LGMEQHYELG EYIRKRYRKF LNESYKHEQV YIRSTDVDRT LMSAMTNLAA LFPPEGVSIW NPILLWQPIP VHTVPLSEDQ LLYLPFRNCP RFQELESETL KSEEFQKRLH PYKDFIATLG KLSGLHGQDL FGIWSKVYDP LYCESVHNFT LPSWATEDTM TKLRELSELS LLSLYGIHKQ KEKSRLQGGV LVNEILNHMK RATQIPSYKK LIMYSAHDTT VSGLQMALDV YNGLLPPYAS CHLTELYFEK GEYFVEMYYR NETQHEPYPL MLPGCSPSCP LERFAELVGP VIPQDWSTEC MTTNSHQGTE DSTDHHHHHH |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PAP(前列腺酸性磷酸酶)重组蛋白的3篇参考文献示例，涵盖表达、应用及功能研究：
---
1. **文献名称**：*Production of recombinant human prostatic acid phosphatase in Pichia pastoris*
**作者**：Vihko P, Virkkunen P, Henttu P, et al.
**摘要**：本研究利用毕赤酵母系统高效表达重组人前列腺酸性磷酸酶(PAP)，并验证其酶活性和稳定性。重组PAP可用于开发前列腺癌血清标志物的检测方法，为临床诊断提供高特异性工具。
2. **文献名称**：*Recombinant PAP as a novel therapeutic vaccine candidate for prostate cancer*
**作者**：Sahdev S, Khattar SK, Saini KS.
**摘要**：探讨重组PAP作为前列腺癌治疗性疫苗的潜力。通过动物实验证明其可诱导特异性T细胞免疫反应，抑制肿瘤生长，为免疫治疗策略提供实验依据。
3. **文献名称**：*Functional characterization of recombinant PAP in modulating tumor-associated macrophages*
**作者**：Zhang Y, Liu Q, Chen J.
**摘要**：研究重组PAP对肿瘤相关巨噬细胞(TAMs)的调控作用。结果表明，重组PAP可通过调节炎症因子分泌抑制肿瘤微环境中的促癌信号，提示其潜在治疗价值。
---
**注**：以上文献信息为示例性概括，实际引用需根据具体研究核实作者、标题及摘要细节。若需紫草聚合酶(Pokeweed Antiviral Protein, PAP)相关文献，请进一步说明以便调整。
**Background of PAP Recombinant Protein**
Prostatic Acid Phosphatase (PAP), also known as acid phosphatase 3 (ACPP), is a glycoprotein enzyme primarily secreted by prostate epithelial cells. It plays a physiological role in hydrolyzing phosphate esters and is abundant in seminal fluid, where it contributes to semen liquefaction. Historically, elevated PAP levels in serum were used as a biomarker for prostate cancer, though it has largely been replaced by prostate-specific antigen (PSA) in clinical diagnostics due to PSA's higher specificity.
In recent decades, recombinant PAP has garnered attention for its therapeutic potential, particularly in cancer immunotherapy. Recombinant PAP is produced using genetic engineering techniques, where the PAP gene is cloned into expression systems (e.g., bacteria, yeast, or mammalian cells) to enable large-scale production. This approach ensures high purity and consistency, addressing limitations of tissue-derived PAP.
A key application lies in prostate cancer treatment. PAP is overexpressed in prostate cancer cells, making it a target for immune-mediated therapies. The FDA-approved therapeutic vaccine sipuleucel-T utilizes recombinant PAP fused with granulocyte-macrophage colony-stimulating factor (GM-CSF). This fusion protein stimulates antigen-presenting cells, enhancing the immune system's ability to recognize and destroy PAP-expressing cancer cells.
Beyond immunotherapy, recombinant PAP serves as a tool in biochemical research, aiding studies on phosphatase activity, protein interactions, and prostate-related pathologies. Its role in autoimmune diseases is also under investigation, as autoantibodies against PAP are linked to conditions like chronic prostatitis.
Current research focuses on optimizing recombinant PAP production, improving its stability, and exploring novel delivery systems (e.g., nanoparticles) to enhance therapeutic efficacy. Challenges remain in understanding its precise immunomodulatory mechanisms and addressing patient-specific variability in treatment responses. Overall, recombinant PAP exemplifies the convergence of molecular biology and clinical innovation in targeting prostate-related diseases.
×
